Next 10 |
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as ...
2024-06-25 09:00:00 ET Summary Catalent stock rose 3% after Elevidys label expansion approval by the FDA. Sarepta's stock reached an all-time high after Elevidys label expansion approval. Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candid...
2024-06-21 09:12:53 ET More on Solid Biosciences Buy Solid Biosciences: Unpacking Its Main Value Driver Solid Biosciences gets FDA rare pediatric disease status for DMD therapy William Blair starts Solid Biosciences at outperform Seeking Alpha’s Quant ...
2024-06-21 08:15:07 ET Piper Sandler analyst issues OVERWEIGHT recommendation for SLDB on June 21, 2024 06:49AM ET. The previous analyst recommendation was Overweight. SLDB was trading at $6.3 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-31 06:00:08 ET Biren Amin from Piper Sandler issued a price target of $20.00 for SLDB on 2024-05-31 05:07:00. The adjusted price target was set to $20.00. At the time of the announcement, SLDB was trading at $7.64. The overall price target consensus is at $19.00 ...
2024-05-26 03:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-20 09:58:45 ET More on PTC Therapeutics PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript PTC Therapeuti...
2024-05-16 07:00:04 ET Gena Wang from Barclays issued a price target of $18.00 for SLDB on 2024-05-16 05:10:00. The adjusted price target was set to $18.00. At the time of the announcement, SLDB was trading at $9.69. The overall price target consensus is at $20.00 with h...
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne muscular dystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trial expected Q2 2024 — — Company entered into non-exclusive licensing agreement for use of ...
News, Short Squeeze, Breakout and More Instantly...
Solid Biosciences Inc. Company Name:
SLDB Stock Symbol:
NASDAQ Market:
Solid Biosciences Inc. Website:
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as ...
2024-06-21 08:15:07 ET Piper Sandler analyst issues OVERWEIGHT recommendation for SLDB on June 21, 2024 06:49AM ET. The previous analyst recommendation was Overweight. SLDB was trading at $6.3 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...